<DOC>
	<DOC>NCT01101113</DOC>
	<brief_summary>This study is designed in order to investigate the effect of cinacalcet in combination with routine conventional medical management for treatment of secondary hyperparathyroidism (SHPT) and Ca, P control. This study will compare the efficacy of a cinacalcet-based regimen with unrestricted conventional care (vitamin D and phosphate binders) for achieving the stringent National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) targets for dialysis patients.</brief_summary>
	<brief_title>Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Peritoneal dialysis patients with secondary HPT(iPTH &gt; 300 pg/mL) &gt; 18 yr of age, &lt; 70 had receive PD for &gt; 3 mo, intact PTH level &gt; 300 pg/ml and &lt;1000 pg/ml albumin corrected Ca level &gt;= 9.0 mg/dL pregnant or breastfeeding, had undergone parathyroidectomy within previous 3 mo, are involved in other clinical trial within 30 d had received cinacalcet therapy previously.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>peritoneal dialysis</keyword>
</DOC>